Robert Andrade News Today

DG Capital Management LLC cut its holdings in Fennec Pharmaceuticals Inc (NASDAQ:FENC – Free Report) by 5.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,075,634 shares of the company’s stock after selling 67,465 shares during the period. Fennec Pharmaceuticals accounts […]

~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH...

RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2024 -- Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has...

“More attempts to chill free speech in the ‘free’ State of Florida,” said one Democratic lawmaker.

~ Supports Strategic Discussions and Global Launch Activities ~ ~ Extends Access to Additional Undrawn Capital As Needed During Global PEDMARK® Rollout ~ ~ Facilitates Market Expansion...

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty...

Operator: Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Third Quarter 2023 Earnings and Corporate Update Conference Call.

~ PEDMARK® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October...

RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2023 -- Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter...

RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2023 -- Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming...